Genentech receives breakthrough therapy designation from the FDA for ACE910 subcutaneous therapy for hemophilia A.
IXINITY® provides good bleed control for patients with severe to moderately severe hemophilia B.
New recombinant FVIII therapy reduces bleeding frequency and offers a new option for patients.
Pharmaceutical company donates 2 million international units of protein factor therapies to the World Federation of Hemophilia (WFH).
Octapharma USA launches new co-pay assistance program for eligible patients who use Wilate® to treat von Willebrand disease (VWD).
FDA accepts Bayer's Biologics License Application for new investigational recombinant FVIII therapy to treat hemophilia A in children and adults.
Progress made by Baxter during clinical trial assessing the safety and optimal dosing level of BAX 335, an investigational factor IX (FIX) gene therapy.
New recombinant factor VIIa therapy expected to extend half-life for people with hemophilia A or B with inhibitors.
New Biogen Idec global partnership to use lentiviral vectors in developing gene therapies for hemophilia A and B.
Consider enrolling in clinical trial of HCV drugs designed for people with hemophilia.
eNewsletter Sign Up
Steps for Living
Victory for Women
Donate Your Car